Introduction
Losing 28% of your body weight sounds straightforwardly good — until you ask what, exactly, is coming off. Scale weight doesn't distinguish between fat and muscle. A pound lost from your thigh could be fat tissue or it could be the muscle that powers your stairs, your squat, your metabolism at rest.
This question matters more for retatrutide than for almost any other weight loss drug, simply because of the scale of weight loss involved. Losing 28.3% of body weight (the TRIUMPH-1 average) is a magnitude previously seen mainly with bariatric surgery — and bariatric surgery has a well-documented lean mass loss problem.
The honest answer, based on the best available evidence: some muscle loss happens with retatrutide, as it does with virtually every significant weight loss intervention. The real question is how much, whether it's proportionate, and what you can do about it.
What the Actual Data Shows
The most rigorous evidence on retatrutide and body composition comes from a prespecified substudy of the Phase 2 trial, published in The Lancet Diabetes & Endocrinology. Researchers used DEXA (dual-energy X-ray absorptiometry) — the clinical gold standard for distinguishing fat mass from lean mass — to scan 189 participants with type 2 diabetes before and after treatment.
What they found:
The substudy enrolled 189 participants with type 2 diabetes; a subset with paired baseline and 36-week DEXA scans was used to assess body composition change. Fat mass decreased from baseline by 15.2% (4mg), 26.1% (8mg), and 23.2% (12mg), compared with 4.5% on placebo and 2.6% on dulaglutide.
The published paper does not report a single pooled percentage describing what share of total weight lost was fat versus lean mass across all doses combined — the effect was dose-dependent, not uniform. What the researchers did report, in substance, is that the proportion of lean mass loss relative to total weight loss was broadly comparable to what's seen with other obesity treatments, not disproportionately worse.
Important context about this data:
This substudy was conducted in participants with type 2 diabetes, not the general obesity population this site primarily covers. T2D and general obesity populations can have different baseline body composition and may respond somewhat differently to treatment. TRIUMPH-1 and TRIUMPH-4 — the Phase 3 trials in general obesity populations most relevant to most readers — have not yet published body composition substudy results.
No body composition substudy has been publicly disclosed for the Phase 3 TRIUMPH program at this time. If one is eventually published — from TRIUMPH-1, TRIUMPH-3, or TRIUMPH-4 — it would be the first body composition data in the general obesity population that TRIUMPH-1 and TRIUMPH-4 primarily serve.
A Note on Conflicting Numbers Online
If you search for "retatrutide muscle loss," you'll find a range of claimed percentages — some sources cite 74% fat / 26% lean, others 75-80% fat / 20-25% lean, others 85-90% fat / 10-15% lean. These numbers are inconsistent with each other and, as far as we can determine, are not traceable to a published, peer-reviewed source specific to retatrutide's Phase 3 trials.
We are not going to repeat unverified figures here. The dose-by-dose fat mass reduction figures above (15.2% / 26.1% / 23.2%) are the only numbers from this substudy we can directly attribute to a peer-reviewed source. Until a Phase 3 body composition analysis is published for the general obesity population, that dose-dependent data — not a single pooled percentage — is what's actually known.
Why Some Lean Mass Loss Is Expected (and Not Necessarily Bad)
| Weight Loss Method | Approximate Lean Mass Loss |
|---|---|
| Caloric restriction alone (diet only) | 25–30% of total weight lost |
| GLP-1 receptor agonists (semaglutide, tirzepatide) | 25–40% of total weight lost (varies by study) |
| Retatrutide (Phase 2, T2D population) | Not established as a single figure; fat mass reduction was dose-dependent (15.2–26.1% from baseline). No pooled fat-vs-lean split has been published. |
| Bariatric surgery | ~21–23% of total weight lost at 12 months (higher, ~30%, in the first 3 months) |
Note: figures for diet, other GLP-1 drugs, and bariatric surgery come from separate studies using varying methodologies and populations; direct comparison should be treated as approximate, not exact.
Some lean mass loss accompanies essentially every method of significant weight loss — pharmacological, surgical, or behavioral. The body doesn't lose weight in a way that's 100% selective for fat tissue. Muscle, along with some water, bone mineral, and organ mass, is included in what DEXA scans classify as "lean mass" — it isn't only skeletal muscle.
The relevant clinical question isn't "does any lean mass loss occur" (it does, with everything), but whether the proportion is in a normal, expected range — and the available data suggests retatrutide's proportion is consistent with what's seen elsewhere in this drug class.
Does Retatrutide's Glucagon Component Help or Hurt Muscle Preservation?
This is a legitimate point of scientific uncertainty, and the honest answer is: it could go either way, and the current data doesn't fully resolve it.
The case for glucagon helping: Glucagon receptor activation increases lipolysis (fat breakdown) and fatty acid oxidation. In theory, a drug that more aggressively mobilizes fat stores for energy could spare lean tissue from being broken down for fuel — since the body has an alternative energy source readily available.
The case for glucagon hurting: Glucagon also has counter-regulatory effects on protein metabolism. Chronic glucagon receptor activation can, in some physiological contexts, increase amino acid mobilization from muscle tissue (gluconeogenic substrate), which could theoretically accelerate lean mass loss rather than prevent it.
The published Phase 2 substudy's overall finding — a lean-to-fat split broadly comparable to other obesity treatments — suggests these two competing effects roughly cancel out, or that neither dominates strongly enough to produce a meaningfully different lean mass outcome compared to GLP-1/GIP-only drugs. This is reassuring in one sense (no disproportionate harm) but doesn't support claims that retatrutide is specifically muscle-sparing in a way other drugs aren't.
What You Can Actually Do to Protect Muscle Mass
Regardless of which weight loss drug someone uses, the same evidence-based strategies apply for minimizing lean mass loss during significant weight loss.
Adequate protein intake. Most clinical guidance for patients undergoing substantial pharmacological weight loss suggests targeting 1.0–1.2 grams of protein per kilogram of body weight daily — higher than typical dietary recommendations. Protein provides the amino acids needed to signal muscle protein synthesis and helps offset the catabolic pressure of caloric deficit.
Resistance training. Mechanical loading is the primary stimulus that tells the body to preserve (or build) muscle tissue rather than break it down. Even two to three resistance sessions per week, targeting major muscle groups, has been shown in weight loss research to meaningfully reduce the proportion of lean mass lost compared to no resistance training.
Avoiding excessive caloric deficit. While appetite suppression from retatrutide can lead to very low spontaneous intake, an extremely aggressive deficit increases the relative contribution of muscle breakdown to total weight loss. Working with a physician or dietitian to ensure intake doesn't fall too far below maintenance needs can help.
Adequate sleep. Sleep deprivation independently increases muscle protein breakdown and reduces the muscle-protective effect of resistance training and protein intake. This is a frequently overlooked variable in body composition outcomes.
Monitoring beyond the scale. Tracking body composition — through DEXA scans, bioelectrical impedance devices, or even simple proxies like strength benchmarks and progress photos — gives more useful feedback than scale weight alone. A 30-pound loss that's mostly fat looks and functions very differently than a 30-pound loss that's a meaningful fraction muscle.
Putting the Numbers in Perspective
Because no pooled fat-vs-lean split has been published for retatrutide, we can't responsibly convert TRIUMPH-1's 28.3% average weight loss into a precise lean-mass figure in pounds. Using the broader range seen across GLP-1-class drugs (25–40% of total weight lost as lean mass), a patient starting at 250 lbs who loses 70 lbs on retatrutide would lose somewhere in the range of 18–28 lbs of lean mass and 42–52 lbs of fat mass — a wide range precisely because retatrutide-specific data doesn't yet exist for the general obesity population.
That's still a substantial amount of lean mass to lose in absolute terms — which is exactly why protein intake and resistance training aren't optional extras for patients pursuing this level of weight loss. They're a core part of doing it well rather than just doing it.
Conclusion
Retatrutide does cause some lean mass loss — that much is consistent with every significant weight loss intervention, pharmacological or otherwise. The best available evidence, a DEXA-confirmed Phase 2 substudy in patients with type 2 diabetes, found dose-dependent fat mass reduction (15.2–26.1% from baseline), and researchers described the overall lean-to-fat split as broadly comparable to other obesity treatments — though no single pooled percentage for that split has been published.
What's still unknown is whether this proportion holds in the general obesity population studied in TRIUMPH-1 and TRIUMPH-4, where total weight loss is substantially higher than the Phase 2 T2D cohort. No Phase 3 body composition data has been published yet to confirm this either way.
In the meantime, the practical takeaway doesn't change much regardless of the exact percentage: adequate protein intake and resistance training are the two most evidence-backed tools for minimizing lean mass loss on any significant weight loss therapy, including retatrutide.
For a complete picture of what to expect on retatrutide, see our complete side effects guide.
Sources
- Coskun T, et al. "Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial." The Lancet Diabetes & Endocrinology, 2025;13(8):674-684.
- Rosenstock J, Frias J, Jastreboff AM, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes." The Lancet, 2023;402:529-544.
- Nuijten MAH, et al. "The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: a systematic review and meta-analysis." Obesity Reviews, 2022;23(1):e13370.
- Jastreboff AM, et al. TRIUMPH-1 Phase 3 topline results (May 21, 2026).
Frequently asked questions
Yes, to a degree that appears similar to other significant weight loss methods, though no single precise percentage has been published. A DEXA-confirmed Phase 2 substudy in type 2 diabetes patients found dose-dependent fat mass reduction (15.2–26.1% from baseline across doses), and researchers described the overall lean-to-fat proportion as comparable to other obesity treatments, not disproportionately worse.
No single confirmed percentage exists yet for retatrutide specifically. Based on the broader GLP-1 drug class (25–40% of total weight lost as lean mass), someone losing 70 lbs on retatrutide might lose roughly 18–28 lbs of lean mass — but this hasn't been confirmed by a published retatrutide-specific figure for the general obesity population.
It's unclear. Glucagon increases fat burning, which theoretically could spare muscle, but it also affects protein metabolism in ways that could increase muscle breakdown. The available data suggests these effects roughly balance out, since retatrutide's lean mass loss proportion is similar to other GLP-1-class drugs.
The two most evidence-backed strategies are adequate protein intake (1.0–1.2g per kg body weight daily) and resistance training 2–3 times per week. Adequate sleep and avoiding an excessively aggressive caloric deficit also support lean mass preservation.
